Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 172

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON

Open access
Hartmaier, Ryan J., Markovets, Aleksandra A., Ahn, Myung Ju, Sequist, Lecia V., Han, Ji-Youn, Cho, Byoung Chul, Yu, Helena A., Kim, Sang-We, Yang, James Chih-Hsin, Lee, Jong-Seok, Su, Wu-Chou, Kowalski, Dariusz M., Orlov, Sergey, Ren, Song, Frewer, Paul, Ou, Xiaoling, Cross, Darren A.E., Kurian, Nisha, Cantarini, Mireille, Jänne, Pasi A. · 2023 · Cancer Discovery

Abstract

MET-inhibitor and EGFR tyrosine kinase inhibitor (EGFR-TKI) combination therapy could overcome acquired MET-mediated osimertinib resistance. We present the final phase Ib TATTON (NCT02143466) analysis (Part B, n = 138/Part D, n = 42) assessing oral savolitinib 600 mg/300 mg once daily (q.d.) + osimertinib 80 mg q.d. in patients with MET-amplified, EGFR-mutated (EGFRm) advanced non–small cell lung cancer (NSCLC) and progression on prior EGFR-TKI. An acceptable safety profile was observed. In Parts B and D, respectively, objective response rates were 33% to 67% and 62%, and median progression-free survival (PFS) was 5.5 to 11.1 months and 9.0 months. Increased antitumor activity may occur with MET copy number ≥10. EGFRm circulating tumor DNA clearance on treatment predicted longer PFS in patients with detectable baseline ctDNA, while acquired resistance mechanisms to osimertinib + savolitinib were mediated by MET, EGFR, or KRAS alterations. Significance: The savolitinib + osimertinib combination represents a promising therapy in patients with MET-amplified/overexpressed, EGFRm advanced NSCLC with disease progression on a prior EGFR-TKI. Acquired resistance mechanisms to this combination include those via MET, EGFR, and KRAS. On-treatment ctDNA dynamics can predict clinical outcomes and may provide an opportunity to inform earlier decision-making. This article is highlighted in the In This Issue feature, p. 1

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-22-0586

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 172

Metadata

Authors
Hartmaier, R. J., Markovets, A. A., Ahn, M. J., Sequist, L. V., Han, J.-Y., Cho, B. C., Yu, H. A., Kim, S.-W., Yang, J. C.-H., Lee, J.-S., Su, W.-C., Kowalski, D. M., Orlov, S., Ren, S., Frewer, P., Ou, X., Cross, D. A. E., Kurian, N., Cantarini, M., & Jänne, P. A.
Venue
Cancer Discovery
Published
2022-10-20
Volume
13
Issue
1
Pages
98-113
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W4306914356
Cited by
172
References
13
FWCI
19.03
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON. https://app.cochat.ai/papers/10.1158/2159-8290.cd-22-0586
The paper
Hartmaier, R. J., Markovets, A. A., Ahn, M. J., Sequist, L. V., Han, J.-Y., Cho, B. C., Yu, H. A., Kim, S.-W., Yang, J. C.-H., Lee, J.-S., Su, W.-C., Kowalski, D. M., Orlov, S., Ren, S., Frewer, P., Ou, X., Cross, D. A. E., Kurian, N., Cantarini, M., & Jänne, P. A. (2023). Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-22-0586

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.